Cancer
Eli Lilly’s business development team has inked 14 buyouts this year so far, with Calytrix Bio tucking into the pharma’s oncology pipeline.
The FDA rejected Summit Therapeutics’ ivonescimab over the weekend, sending a strong message to rival drugmakers Bristol Myers Squibb, BioNTech, Pfizer, Merck and AbbVie.
The FDA has denied an approval for Summit Therapeutics’ ivonescimab to treat EGFR-mutated non-small cell lung cancer, blocking the drug’s entry to the U.S. after it became available in China in 2024.
When Ionis Pharmaceuticals’ Tryngolza undersold, investors immediately looked to Arrowhead Pharmaceuticals’ executives for answers on how they will navigate a launch in the same market.
While Moderna preps an entry to the oncology market next year with a personalized cancer vaccine, COVID sales are holding steady with several other vaccine launches underway around the world.
Also lined up are target action dates for Sanofi’s Gaucher disease therapy, GSK’s lung cancer medicine and BridgeBio’s muscular dystrophy drug.
Pent-up demand for the new pancreatic cancer therapy Rasonque helped RevMed soar past analysts’ sales expectations and reach 5,000 patients in the third quarter.
In this episode of Denatured, you’ll hear from from Lewis Bender, CEO at Intensity Therapeutics and Paul-Peter Tak, president, CEO and board director at Candel Therapeutics. We explore how intratumoral therapies trigger systemic anticancer immunity from a local injection, and redefine a foundational platform in immuno-oncology.
Boehringer Ingelheim is building up its China strategy, inking a deal to develop new cancer treatments with Sino Biopharmaceutical just weeks after opening an R&D facility in Shanghai.
Sanofi has discontinued an early-stage STAT6 degrader program licensed from Nurix Therapeutics, a decision analysts say is related to the asset itself or Sanofi’s strategic reprioritization rather than the drug class more broadly.
PRESS RELEASES